%0 Case Reports
%T Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report.
%A Fletcher JA
%A Mullally WJ
%A Ladwa R
%A O'Byrne KJ
%J JTO Clin Res Rep
%V 5
%N 2
%D 2024 Feb
%M 38357093
暂无%R 10.1016/j.jtocrr.2023.100591
%X ALK gene rearrangements are detected in approximately 3% to 5% of NSCLC. ALK tyrosine kinase inhibitors, such as third-generation lorlatinib, have exhibited remarkable efficacy in ALK-rearranged NSCLC; however, they have been associated with a low incidence of treatment-limiting and potentially fatal drug-induced interstitial lung disease (ILD). There is concern that this may represent a class effect, a theory that is supported by a number of case reports. Because of clinical trial exclusion criteria, there are limited prospective data to guide decision-making after ALK tyrosine kinase inhibitors-induced ILD. A systematic review of the literature was conducted and only identified four reported cases of lorlatinib safety in this context. Here, we report the successful sequencing of lorlatinib in a patient who discontinued alectinib secondary to grade 3 drug-induced ILD.